Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Krabbe Disease Treatment Market (2018-2022) to Grow at a CAGR of 7.24% with GlaxoSmithKline, Johnson & Johnson and Novartis Dominating -

Research and Markets
Posted on: 14 Feb 18

The "Global Krabbe Disease Treatment Market 2018-2022" report has been added to's offering.

Global krabbe disease treatment market to grow at a CAGR of 7.24% during the period 2018-2022.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is emergence of pharmacological chaperone therapy. More than two-fifth known cases of Krabbe disease are due to missense mutation in the GLC enzyme. Such mutations result in the disruption of enzyme folding and ultimately stops the GLC from reaching its site of action in enough amounts in the lysosome.

According to the report, one driver in the market is special drug designation. An important factor that is expected to drive market growth is the assignment of special drug designations to drugs and biologics that are intended for the safe and effective treatment of Krabbe disease. The priority review program for facilitating fast drug approvals is offered by the Food and Drug Administration (FDA).

Further, the report states that one challenge in the market is limited patient pool for clinical trials.

Key Vendors

  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Pipeline Analysis

Part 09: Market Segmentation by Therapy

Part 10: Customer Landscape

Part 11: Regional Landscape

Part 12: Decision Framework

Part 13: Drivers and Challenges

Part 14: Market Trends

Part 15: Vendor Landscape

Part 16: Vendor Analysis

For more information about this report visit

View source version on

Business Wire

Last updated on: 14/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.